Emyria (ASX: EMD) is preparing to open its first Sydney clinic in September, with the company saying key operational milestones...

New Zealand has authorised two psychiatrists to prescribe pharmaceutical-grade MDMA as part of supervised treatment for adults with post-traumatic stress...

BLS Pharmaceuticals Limited (ASX: BLS) has appointed Zivana Crestani as Strategic Partnership Director, adding to the company's commercial leadership as...

Ensysce Biosciences will participate in the U.S. Food and Drug Administration's September 14 public hearing on the potential future therapeutic...

With six weeks to go until SCALE 2026, the international mental health and psychedelic medicine community is preparing to gather...

Australia's listed cannabis sector has become increasingly difficult to define simply as "cannabis". The latest results show companies moving in...

BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising...

Psychedelic medicine has spent the past decade developing clinical evidence almost exclusively in adults. Adolescents have largely remained outside the...

For decades, psychedelic medicine sat on the margins of psychiatry, constrained by international drug controls, political controversy and the legacy...

The psychedelic industry has no shortage of drug developers, clinical trials or investment pitches. What it has less of is...